Skip to main
FATE

Fate Therapeutics (FATE) Stock Forecast & Price Target

Fate Therapeutics (FATE) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Fate Therapeutics is estimated to have a market value of $814M by the end of 2026, taking into account their current cash reserves of $175M. The incorporation of a 20% probability of approval for their FT819 drug in SLE and a 1.5% terminal growth rate contribute to the overall positive outlook. While risks such as potential safety concerns and regulatory backlash exist, positive preliminary results from a Phase 1 trial evaluating their MICA/B show potential for anti-tumor activity, with a significant reduction in target lesions and tumor biomarker observed. Furthermore, their FT836 combination therapy is well-tolerated with no severe side effects observed.

Bears say

Fate Therapeutics is projected to have a market value of $826M in 2025 based on a discounted cash flow valuation, which takes into account the company's cash and investments. However, there is a high level of uncertainty surrounding the success of their leading product candidate, FT819, which has only a 20% probability of approval for SLE. The company also faces potential risks such as safety concerns and potential dilution.

Fate Therapeutics (FATE) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Fate Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Fate Therapeutics (FATE) Forecast

Analysts have given Fate Therapeutics (FATE) a Buy based on their latest research and market trends.

According to 3 analysts, Fate Therapeutics (FATE) has a Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Fate Therapeutics (FATE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.